The phase 3 PaTHway trial finds TransCon PTH frees most adults with hypoparathyroidism from conventional therapy and halves urinary calcium. PICO summary and expert commentary.
Author: Hormone Insight Editorial Team
Read More
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.
A 13-week single-arm switch study tested inhaled technosphere insulin plus degludec against participants’ own baseline in 49 adults with type 1 diabetes. PICO summary and expert commentary.
An open-label trial found that pioglitazone/metformin plus dapagliflozin did not beat basal insulin/metformin on its primary glycaemic endpoint, with secondary metabolic signals favouring the oral regimen. PICO summary and expert commentary.
Summary: In Chinese adults with type 2 diabetes, a 6-month low-calorie diet achieved diabetes remission in 56% of participants, with formula-based and real food-based diets performing equally well and notable individual variability in response. PICO Summary ElementDetailPopulationChinese adults with type 2 diabetes (BMI 24–45 kg/m², HbA1c 6.5–12.0%); n=41.InterventionLow-calorie diet, 815–835 kcal/day for 3 months then a 3-month maintenance phase; formula-based (LCFD, n=21) and real food-based (LCRFD, n=20) variants. All anti-diabetic drugs stopped on day 1.ComparisonLCFD versus LCRFD head-to-head; remission rates also benchmarked against published data from other populations.Outcome56.1% achieved T2D remission at 6 months; 39.0% lost ≥10% body weight. Significant…
Summary: In adults with chronic kidney disease and overweight or obesity but without diabetes, semaglutide 2.4 mg once weekly for 24 weeks reduced urine albumin-to-creatinine ratio by 52% compared with placebo, with more frequent but expected gastrointestinal side effects. PICO Summary ElementDetailPopulationAdults with CKD (eGFR ≥25 ml/min/1.73 m², UACR 30–3,500 mg/g) and BMI ≥27 without diabetes (n=101).InterventionSemaglutide 2.4 mg subcutaneous weekly for 24 weeks, titrated per protocol.ComparisonMatching placebo injection weekly for 24 weeks.OutcomeUACR reduced by 52.1% versus placebo (95% CI -65.5 to -33.4; P<0.0001). Gastrointestinal adverse events more frequent with semaglutide (30 vs 15 participants). Expert Commentary For the obese…
An RCT finds lower-limb resistance training improves glycaemic control and quality of life in diabetic foot ulcer patients, but not wound healing. PICO summary and commentary.
A phase 3 trial finds recombinant human TSH non-inferior to thyroid hormone withdrawal for radioiodine ablation in intermediate-risk thyroid cancer, with fewer adverse events. PICO summary and commentary.
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context The GLP-1 receptor agonist class has transformed type 2 diabetes management, with semaglutide emerging as a particularly effective agent for both glycemic control and weight loss. However, the development of tirzepatide—a novel dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors—raised the question of whether engaging two incretin pathways could outperform single-target GLP-1 agonism. SURPASS-2 represents the definitive head-to-head comparison: tirzepatide versus semaglutide 1.0 mg (the maximum approved dose for type 2 diabetes) in a Phase 3 randomized controlled trial.…
An open-label phase 3 noninferiority trial finds recombinant human thyrotropin matches thyroid hormone withdrawal for radioactive iodine ablation success in intermediate-risk differentiated thyroid cancer, with fewer adverse events. PICO summary and expert commentary.